Latest Insider Transactions at Cytokinetics Inc (CYTK)
This section provides a real-time view of insider transactions for Cytokinetics Inc (CYTK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CYTOKINETICS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CYTOKINETICS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 20
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$62,000
$31.98 P/Share
|
|
May 20
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
May 16
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.2%
|
$150,000
$30.93 P/Share
|
|
May 15
2025
|
Muna Bhanji Director |
SELL
Open market or private sale
|
Direct |
1,454
-5.82%
|
$42,166
$29.73 P/Share
|
|
May 14
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+24.73%
|
-
|
|
May 14
2025
|
B Lynne Parshall Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+20.79%
|
-
|
|
May 14
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+9.05%
|
-
|
|
May 14
2025
|
Muna Bhanji Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+22.7%
|
-
|
|
May 14
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+18.05%
|
-
|
|
May 14
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+18.56%
|
-
|
|
May 14
2025
|
Robert E Landry Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+50.0%
|
-
|
|
May 14
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,333
+19.33%
|
-
|
|
May 06
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$70,000
$35.01 P/Share
|
|
May 06
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
May 05
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
4,002
-6.19%
|
$144,072
$36.68 P/Share
|
|
Apr 29
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.18%
|
$200,000
$40.96 P/Share
|
|
Apr 22
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$76,000
$38.11 P/Share
|
|
Apr 22
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
Apr 21
2025
|
Wendall Wierenga Director |
SELL
Open market or private sale
|
Direct |
20,000
-44.6%
|
$760,000
$38.46 P/Share
|
|
Apr 21
2025
|
Wendall Wierenga Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+30.84%
|
$120,000
$6.21 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
SELL
Open market or private sale
|
Direct |
3,190
-4.59%
|
$121,220
$38.66 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+22.34%
|
$120,000
$6.21 P/Share
|
|
Apr 15
2025
|
Edward M. Md Kaye Director |
BUY
Grant, award, or other acquisition
|
Direct |
324
+1.23%
|
$12,312
$38.56 P/Share
|
|
Apr 15
2025
|
Robert Arthur Harrington Director |
BUY
Grant, award, or other acquisition
|
Direct |
324
+2.12%
|
$12,312
$38.56 P/Share
|
|
Apr 15
2025
|
John T Henderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
551
+0.82%
|
$20,938
$38.56 P/Share
|
|
Apr 15
2025
|
Nancy Wysenski Director |
BUY
Grant, award, or other acquisition
|
Direct |
162
+0.69%
|
$6,156
$38.56 P/Share
|
|
Apr 15
2025
|
Wendall Wierenga Director |
BUY
Grant, award, or other acquisition
|
Direct |
162
+0.65%
|
$6,156
$38.56 P/Share
|
|
Apr 10
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.17%
|
$180,000
$36.77 P/Share
|
|
Apr 08
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.41%
|
$72,000
$36.18 P/Share
|
|
Apr 08
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.39%
|
$20,000
$10.6 P/Share
|
|
Apr 07
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,886
-4.27%
|
$101,010
$35.78 P/Share
|
|
Apr 03
2025
|
Robert Arthur Harrington Director |
SELL
Open market or private sale
|
Direct |
450
-2.98%
|
$17,550
$39.43 P/Share
|
|
Mar 31
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
15,000
-3.39%
|
$600,000
$40.75 P/Share
|
|
Mar 19
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Bona fide gift
|
Direct |
200
-0.14%
|
-
|
|
Mar 18
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
2,000
-1.4%
|
$86,000
$43.58 P/Share
|
|
Mar 18
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+1.38%
|
$20,000
$10.6 P/Share
|
|
Mar 17
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
37,648
-5.3%
|
$1,656,512
$44.52 P/Share
|
|
Mar 17
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
4,389
-4.16%
|
$193,116
$44.38 P/Share
|
|
Mar 17
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
23,675
-21.53%
|
$1,041,700
$44.76 P/Share
|
|
Mar 17
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
20,900
+26.3%
|
$480,700
$23.26 P/Share
|
|
Mar 14
2025
|
Sung Lee EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,687
+30.51%
|
-
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,687
+31.72%
|
-
|
|
Mar 14
2025
|
Fady Ibraham Malik EVP Research & Development |
BUY
Grant, award, or other acquisition
|
Direct |
39,450
+21.41%
|
-
|
|
Mar 14
2025
|
Robert I Blum President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
116,096
+19.47%
|
-
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
100
-0.26%
|
$4,500
$45.0 P/Share
|
|
Mar 14
2025
|
Andrew Callos EVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
100
+0.26%
|
$2,300
$23.26 P/Share
|
|
Mar 13
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
26,771
-41.55%
|
$1,151,153
$43.62 P/Share
|
|
Mar 06
2025
|
Fady Ibraham Malik EVP Research & Development |
SELL
Open market or private sale
|
Direct |
8,228
-7.24%
|
$353,804
$43.27 P/Share
|
|
Mar 06
2025
|
Andrew Callos EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,341
-4.93%
|
$143,663
$43.27 P/Share
|
|
Mar 06
2025
|
Robert I Blum President & CEO |
SELL
Open market or private sale
|
Direct |
16,970
-4.45%
|
$729,710
$43.44 P/Share
|